MedTrace Logo

Treatment of PED With AMT and Autologous Serum

NCT00238862 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2021-12-02

No results posted yet for this study

Summary

Patients with persistent corneal epithelial defects who have not responded to conventional therapy will be randomized to treatment with either amniotic membrane transplantation or autologous serum 20%. Outcome measures will be (1) presence or absence of complete re-epithelialization within 28 days and (2) retention of intact epithelium for at least 90 days.

Conditions

  • Corneal Epithelial Defect

Interventions

PROCEDURE

Amniotic membrane transplantation

DRUG

Autologous serum/BSS 20%

Sponsors & Collaborators

  • King Khaled Eye Specialist Hospital

    lead OTHER_GOV

Principal Investigators

  • Michael D Wagoner, MD · King Khaled Eye Specialist Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Completion
2006-09-30

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00238862 on ClinicalTrials.gov